ANGLE reports encouraging results from Parsortix oesophageal cancer study Oesophageal cancer is a deadly disease with 80% patient mortality at 5 years from diagnosis, partly due to late diagnosis ANGLE PLC (LON:AGL) said that a study at the University Hospital Ghent, Belgium showed its liquid biopsy system Parsortix consistently harvested oesophageal cancer cells in patients suffering from the disease. These are the first published results in this cancer type, said ANGLE, and means the Parsortix system is now validated in 24 cancer types in 28 independent cancer research centres located across 11 countries. Researchers in Belgium utilised ANGLE's marker-independent Parsortix system to isolate epithelial circulating tumour cells (CTCs) in patients and then performed cell-based image analysis to compare cell morphology and characteristics.